← All medicines
Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)
Licence EU/1/23/1740/001-002 · Unknown
- Licence holder
- GlaxoSmithKline Biologicals (all products →)
- Active substance
- Recombinant respiratory syncytial virus pre-fusion F protein, adjuvanted with AS01E
- Dosage form
- Powder and suspension for suspension for injection
- Route of administration
- Intramuscular use
- ATC code
- J07BX05
- First authorised
- 06/06/2023
- Prescription status
- Product subject to prescription which may not be renewed (A)
- Supply
- Supply through pharmacies only
- Legal basis
- Full application (Article 8(3) of Directive No 2001/83/EC)
Data: Health Products Regulatory Authority (HPRA) open dataset, licensed CC BY 4.0, published 04 Jul 2026. This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.